Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has announced the cancellation of 23,505 of its ordinary fully paid shares as part of an on-market buy-back program, effective April 26, 2024. This strategic move is aimed at managing the company’s capital and could potentially signal confidence in its financial health to investors.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
